A Cancer-Linked Chemical In Tap Water May Be More Dangerous For Kids Than Adults

A chemical found in drinking water, processed foods, and some medications appears far more harmful to developing bodies than to adults. And it’s not because young tissues absorb more of it. In mice engineered to have reduced DNA repair capacity, a brief early-life exposure produced persistent signs of DNA damage and later mutations, and eventually liver cancer, while adults given the identical dose came through with far fewer harmful consequences.

That’s the conclusion of a new study from researchers at MIT and collaborating institutions, published in Nature Communications. Importantly, the most dramatic effects, including cancer development, occurred in DNA repair-deficient mice, a model designed to amplify biological signals that might otherwise be too subtle to detect. Normal mice with intact repair systems showed a similar but weaker pattern, and tumor increases in that group did not reach statistical significance.

Still, the findings raise serious questions about whether current safety standards, largely built on studies in adult animals, are adequately accounting for the risks of early-life exposure.

How NDMA Exposure Affected Young vs. Adult Mice

NDMA, short for N-nitrosodimethylamine, is a probable human carcinogen. It made national headlines when discovered in widely prescribed heartburn and blood pressure medications, triggering major recalls. It also turns up in certain foods, cigarette smoke, and drinking water.

In what the authors describe as the first in-depth, direct comparison with adults, the research team, led by Bevin P. Engelward at MIT, gave both DNA repair-deficient and normal mice NDMA in their drinking water at 5 parts per million for two weeks. Juveniles started at around three weeks old; adults at around three months old.

In the young, repair-deficient mice, the consequences were rapid. DNA break markers shot up, inflammation took hold in the liver, immune cells flooded the tissue, and cells began dying and regenerating in a destructive cycle. In adults given the identical dose, these effects barely registered.

Ten days after exposure ended, juvenile mice still showed unresolved DNA damage and inflammation. Three months later, young mice had accumulated far more mutations than adults.

Why Cell Division Made NDMA So Much Worse in Young Mice

Using specialized mutation-detection tools, the team found juvenile mice developed far higher rates of both small-scale DNA changes and large-scale genetic rearrangements. Young, repair-deficient mice had roughly 186 times more mutations per unit of DNA than unexposed controls; adults had about 51 times more, still elevated but 3.6 times lower than in juveniles. Mutant cells in juvenile mice were also multiplying and expanding, an early cancer marker that did not appear in adults.

When researchers examined mice 10 to 11 months after their brief exposure, NDMA-treated juveniles showed liver cell enlargement, abnormal tissue growth, and ongoing cell death, all features associated with cancer progression. Their body weight had dropped about 20 percent compared to unexposed controls. Liver cancer was the most common tumor type and appeared only in exposed juveniles. Lung tumors and a type of lymph node cancer also appeared exclusively in the young, exposed group.

Perhaps the study’s most revealing finding concerns why age matters so much. Measured levels of the DNA damage products NDMA leaves behind were essentially the same in juveniles and adults, as were levels of the enzyme that converts NDMA into its harmful form. The difference came down to cell division.

Juvenile mouse livers were growing rapidly, with over five times more actively dividing cells than adult livers. When dividing cells encounter chemically damaged DNA, they can lock in permanent mutations or trigger chromosomal breaks. In a dormant adult liver, the same damage is often repaired before causing harm.

To test that theory, the researchers gave adult mice T3, a hormone that stimulates liver cell division, mimicking the rapid growth seen in juveniles. Exposed adult cells showed a 3.5-fold jump in large-scale mutations, partially reproducing juvenile vulnerability and confirming the core mechanism: rapid cell growth transforms temporary chemical damage into lasting genetic harm.

Sex Differences and What Low Doses Revealed

Among juvenile mice, males fared worse, showing higher DNA break markers, more mutations at every time point, and a two-fold higher long-term mutation burden. Female mice showed a stronger activation of a protein that slows cell division, giving cells more repair time, which likely shielded them from the worst effects.

Even at a dose 1,000 times lower, 5 parts per billion, juvenile mice showed signs of stress in liver cells and a small but significant increase in large-scale mutations. The broader inflammatory changes seen at higher doses were not present.

What the NDMA Findings Could Mean for Children

These experiments were conducted in mice, not humans. But the DNA repair systems, metabolic pathways, and age-related biological processes involved are shared across mammals. Mutation patterns in NDMA-treated mice closely match signatures seen in human cancers linked to the same chemical damage. Researchers also point to an epidemiological study from Wilmington, Massachusetts, finding a statistical association between prenatal NDMA exposure and childhood cancer.

Safety factors used to set public exposure limits, the authors argue, may underestimate risk to children. NDMA contamination continues to surface in water systems and consumer products. What this research adds is a serious warning signal from animal data: the dose that appears safe for an adult may not be the right benchmark when developing bodies are involved.

---

Disclaimer: This study was conducted in mice and does not establish that current NDMA exposure levels are unsafe for humans. The findings should not be interpreted as personal medical advice. If you have concerns about chemical exposure or your health, consult a qualified healthcare provider.

---